The HGSNAT Knockout NCI-H1975 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population generated through targeted disruption of the HGSNAT gene. This loss-of-function model enables investigation of heparan sulfate catabolism and lysosomal storage disorder mechanisms in a human cancer cell background. The polyclonal population preserves the inherent genetic heterogeneity of edited cells, offering a robust system for studying population-level responses to HGSNAT ablation without clonal selection bias. Researchers can utilize this product for deep phenotypic and mechanistic analyses in pathways requiring stepwise lysosomal degradation of glycosaminoglycans.
NCI-H1975 serves as the host cell line, derived from a non-small cell lung adenocarcinoma with prominent EGFR L858R/T790M mutations from a female patient. This malignant lung epithelial model is widely employed in oncology and targeted therapy research due to its well-characterized signaling dependencies and drug resistance profiles. The cell line??s defined genetic background allows for correlative studies linking lysosomal perturbations to oncogenic driver mutations, providing a unique platform to explore the intersection of lysosomal function and tumor cell biology.
HGSNAT encodes a lysosomal acetyltransferase that catalyzes the N-acetylation of terminal glucosamine residues during heparan sulfate degradation, a key step in glycosaminoglycan catabolism. Its activity lies downstream of N-sulfoglucosamine sulfohydrolase (SGSH) and upstream of N-acetyl-alpha-glucosaminidase (NAGLU) and alpha-L-iduronidase (IDUA) within the heparan sulfate degradation complex. The enzyme is transcriptionally regulated by TFEB, a master regulator of lysosomal biogenesis that responds to lysosomal stress. HGSNAT-mediated acetylation generates acetylated heparan sulfate intermediates essential for subsequent hydrolysis; disruption leads to accumulation of non-acetylated fragments, compromising lysosomal homeostasis and recapitulating the molecular hallmarks of mucopolysaccharidosis type IIIC (Sanfilippo syndrome C).
In the NCI-H1975 context, HGSNAT knockout drives lysosomal dysfunction that intersects with the cell??s malignant phenotype. The accumulation of non-acetylated heparan sulfate species triggers lysosomal stress signaling, potentially modulating autophagy-lysosome pathway dynamics and intersecting with EGFR-driven survival cues. This model allows dissection of how lysosomal catabolic defects influence cancer cell metabolism, proliferation, and stress adaptation, while simultaneously serving as a disease-in-a-dish system for Sanfilippo syndrome C pathology. The polyclonal nature of the knockout population enables assessment of functional heterogeneity in lysosomal responses.
Key research applications include mucopolysaccharidosis type IIIC disease modeling, heparan sulfate metabolism studies, autophagy-lysosome pathway analysis, and drug screening for lysosomal storage disorders. Representative assays encompass Western blotting for HGSNAT protein, RT-qPCR quantification of transcript levels, immunofluorescence staining of lysosomal compartments, enzymatic activity measurements for pathway components, heparan sulfate fragment quantification, autophagy flux monitoring, lysosomal pH assessment, and drug sensitivity profiling. The model is particularly suited for identifying small molecules that restore lysosomal function or bypass heparan sulfate degradation impairments. For further technical specifications or collaborative inquiries, please contact Ascent Research.
